Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study

Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study

Emerging data suggest suboptimal antibody responses to COVID-19 vaccination in patients with hematological malignancies. We evaluated the humoral response following the BNT162b2 vaccine in patients with chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), and Hodgkin’s lymphoma (HL). An...

Full description

Bibliographic Details
Main Authors: Evangelos Terpos, Maria Gavriatopoulou, Despina Fotiou, Chara Giatra, Ioannis Asimakopoulos, Maria Dimou, Aimilia D. Sklirou, Ioannis Ntanasis-Stathopoulos, Ismini Darmani, Alexandros Briasoulis, Efstathios Kastritis, Maria Angelopoulou, Ioannis Baltadakis, Panayiotis Panayiotidis, Ioannis P. Trougakos, Theodoros P. Vassilakopoulos, Maria Pagoni, Meletios A. Dimopoulos
Format: Article
Language:English
Published: MDPI AG 2021-09-01
Series:Cancers
Subjects:
SARS-CoV-2
COVID-19 vaccination
BNT162b2 vaccine
chronic lymphocytic leukemia
non-Hodgkin’s lymphoma
Hodgkin’s lymphoma
Online Access:https://www.mdpi.com/2072-6694/13/17/4480

Internet

https://www.mdpi.com/2072-6694/13/17/4480

Similar Items